JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB213480

Anti-PD-L1 antibody [EPR20529]

  • RabMAb
  • Recombinant
  • KO Validated
  • 20ul selling size
  • What is this?

5

(5 Reviews)

|

(131 Publications)

Anti-PD-L1 antibody [EPR20529] (ab213480) is a rabbit monoclonal antibody detecting PD-L1 in Western Blot, IP, ICC/IF. Suitable for Mouse.

- KO validated for confirmed specificity
- Biophysical QC for unrivalled batch-batch consistency
- Over 70 publications

View Alternative Names

CD274, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1, Cd274, Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1

5 Images
Immunocytochemistry/ Immunofluorescence - Anti-PD-L1 antibody [EPR20529] (AB213480)
  • ICC/IF

Lab

Immunocytochemistry/ Immunofluorescence - Anti-PD-L1 antibody [EPR20529] (AB213480)

ab213480 staining PD-L1 in RAW264.7 from Mouse macrophage cell line transformed with Abelson murine leukemia virus by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with 100% Methanol. Samples were incubated with ab213480 at 0.4 μg/ml. AlexaFluor®488 Goat anti-Rabbit (ab150077) was used as the secondary antibody at 2 μg/ml. Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594)(ab196889) was used as counterstain at 2.5 μg/ml. DAPI used as nuclear counterstain. Confocal image showing membranous staining on RAW 264.7 cells treated with IFN-γ (100 ng/ml) for 24 hours.

Immunoprecipitation - Anti-PD-L1 antibody [EPR20529] (AB213480)
  • IP

Supplier Data

Immunoprecipitation - Anti-PD-L1 antibody [EPR20529] (AB213480)

PD-L1 was immunoprecipitated from 0.35 mg of Mouse placenta lysate with ab213480 at 1/30 dilution.

Western blot was performed from the immunoprecipitate using ab213480 at 1/500 dilution.

VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/1,000 dilution.

Lane 1 : Mouse placenta lysate, 10 μg (Input).

Lane 2 : ab213480 IP in mouse placenta lysate.

Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab213480 in mouse placenta lysate.

Blocking and dilution buffer and concentration : 5% NFDM/TBST.

Exposure time : 3 seconds.

All lanes:

Immunoprecipitation - Anti-PD-L1 antibody [EPR20529] (ab213480)

Predicted band size: 33 kDa

Observed band size: 55-60 kDa

false

Western blot - Anti-PD-L1 antibody [EPR20529] (AB213480)
  • WB

Supplier Data

Western blot - Anti-PD-L1 antibody [EPR20529] (AB213480)

Blocking/Dilution buffer : 5% NFDM/TBST.

The molecular weight observed is consistent with what has been described in the literature. PMID : 15353579.

All lanes:

Western blot - Anti-PD-L1 antibody [EPR20529] (ab213480) at 1/1000 dilution

All lanes:

Mouse placenta lysate at 10 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Predicted band size: 33 kDa

Observed band size: 40-60 kDa

false

Exposure time: 15s

Western blot - Anti-PD-L1 antibody [EPR20529] (AB213480)
  • WB

Lab

Western blot - Anti-PD-L1 antibody [EPR20529] (AB213480)

This WB was performed by using YCA-R20529(BF)-111A H3L2 YR120921PJ, 1 : 5000 dilution. Working concentration : 0.402 μg/ml.

Blocking buffer and concentration : 5% NFDM/TBST

Diluting buffer and concentration : 5% NFDM/TBST

All lanes:

Western blot - Anti-PD-L1 antibody [EPR20529] (ab213480) at 1/5000 dilution

Lane 1:

Untreated RAW264.7 (mouse Abelson murine leukemia virus-induced tumor macrophage) whole cell lysate at 20 µg

Lane 2:

RAW264.7 treated with 100 ng/ml IFN gamma for 48 h, whole cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Predicted band size: 33 kDa

Observed band size: 40-60 kDa

false

Exposure time: 37s

Western blot - Anti-PD-L1 antibody [EPR20529] (AB213480)
  • WB

AbReview78135****

Western blot - Anti-PD-L1 antibody [EPR20529] (AB213480)

The mAb is specific for mouse mPDL1 and does not recognise hPDL1. As expected a specific 48kDa band is observed in RAW264.7 and MEFS cell extract after Interferon-gamma treatment. No bands are observed in RAW264.7 and MEFS WT and in MEFS KO with and without Interferon-gamma treatment.

All lanes:

Western blot - Anti-PD-L1 antibody [EPR20529] (ab213480) at 100 µg

Lane 1:

HEK mPDL1 cell lysate at 20 µg

Lane 2:

HEK hPDL1 cell lysate at 20 µg

Lane 3:

HEK CL7 at 20 µg

Lane 4:

RAW 264.7 Wild-type (Mouse macrophage cell line transformed with Abelson murine leukemia virus) whole cell lysate at 100 µg

Lane 5:

RAW 264.7 (Mouse macrophage cell line transformed with Abelson murine leukemia virus) whole cell lysate treated with Interferon-gamma at 100 µg

Lane 6:

MEF Wild-type (Mouse embryonic fibroblast cell line) whole cell lysate at 100 µg

Lane 7:

MEF (Mouse embryonic fibroblast cell line) whole cell lysate treated with Interferon-gamma at 100 µg

Lane 8:

MEF mPDL1 KO cell lysate at 100 µg

Lane 9:

MEF mPDL1 KO treated with Interferon-gamma at 100 µg

Predicted band size: 33 kDa

Observed band size: 48 kDa

false

Exposure time: 5min

This image is courtesy of an anonymous collaborator.

  • Carrier free

    Anti-PD-L1 antibody [EPR20529] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR20529

Isotype

IgG

Carrier free

No

Reacts with

Mouse

Applications

IP, ICC/IF, WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Specificity

This antibody is not suitable in IHC-FR for mouse samples

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "IHCFr" : {"fullname" : "Immunohistochemistry (Frozen sections)", "shortname":"IHC-Fr"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Mouse": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/30", "IP-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "IHCFr-species-checked": "notRecommended", "IHCFr-species-dilution-info": "", "IHCFr-species-notes": "<p></p>" } } }

Product details

Anti-PD-L1 antibody [EPR20529] (ab213480) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in ICC/IF, IP and WB.

Abcam's high quality manufacturing and validation processes ensure Anti-PD-L1 antibody [EPR20529] (ab213480) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility.

The specificity of Anti-PD-L1 antibody [EPR20529] (ab213480) has been confirmed by Western Blot testing in PD-L1 knockout MEF (mouse embryonic fibroblast) cells.

Anti-PD-L1 antibody [EPR20529] (ab213480) has 5 independent reviews from customers.

Anti-PD-L1 antibody [EPR20529] (ab213480) specifically detects PD-L1 (UniProt ID: Q9EP73; Molecular weight: 31kDa) and is sold in 100 µL and 1 mL selling sizes.

Conjugation-ready, carrier free format available for antibody clone EPR20529 - ab223141.

Programmed death-ligand 1 (PD-L1) is a critical protein in immuno-oncology, playing a significant role in tumor immune evasion. It is expressed on the surface of tumor cells and binds to the PD-1 receptor on T cells, inhibiting their activity and allowing tumors to escape immune detection.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Conditional Ambient
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PD-L1 also known as Programmed Death-Ligand 1 or CD274 is a protein involved in immune modulation. Mechanically PD-L1 interacts with its receptors particularly PD-1 to regulate cellular immune responses. This transmembrane protein has a calculated molecular weight of approximately 33 kDa. PD-L1 is expressed on various cell types including tumor cells and immune cells such as dendritic cells macrophages and B cells. Its expression is often upregulated in response to inflammatory cytokines.
Biological function summary

PD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.

Pathways

PD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.

PD-L1 is most associated with cancer particularly in tumors such as melanoma and non-small cell lung cancer. PD-L1 expression on tumor cells often correlates with poor prognosis. PD-L1 directly interacts with PD-1 in these cancers a target for immunotherapies such as checkpoint inhibitors which aim to block this interaction and restore immune activity against tumors. PD-L1 involvement extends to autoimmune disorders where altered expression can impact tolerance and lead to immune-related tissue damage.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 11238124). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed : 11238124). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed : 11015443, PubMed : 12719480).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 12218188, PubMed : 27281199). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (PubMed : 12218188). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed : 12218188).
See full target information Cd274

Publications (131)

Recent publications for all applications. Explore the full list and refine your search

Journal of nanobiotechnology 23:648 PubMed41074162

2025

Fe-MOF loaded with capmatinib to reverse immunosuppressive microenvironment and inhibit tumor metastasis after radiofrequency ablation.

Applications

Unspecified application

Species

Unspecified reactive species

Jinchao Zhao,Lei Lei,Cheng Zeng,Xianfei Zhou,Junkang Ding,Wenbin Dai,Angfeng Jiang,Shaomin Zou,Qiao Jin,Zhe Tang

Nature communications 16:8804 PubMed41038820

2025

Dual membrane receptor degradation via folate receptor targeting chimera.

Applications

Unspecified application

Species

Unspecified reactive species

Zhen Wang,Zhixin Li,Jenny Högström,Hiroyuki Inuzuka,Rui Jing,Peiqiang Yan,Tao Hou,Yihang Qi,Daoyuan Huang,Jingchao Wang,Ting Wu,Xiaoying Shi,Bolin Liu,Taru Muranen,Dingpeng Zhang,Wenyi Wei

Neoplasia (New York, N.Y.) 69:101222 PubMed40882404

2025

Steatohepatitis alters lymphocytes cytotoxicity and localization, accelerating colorectal liver metastases.

Applications

Unspecified application

Species

Unspecified reactive species

Adi S Yehezkel,Eyal Yehezkel,Nathalie Abudi,Rinat Abramovitch

Cell communication and signaling : CCS 23:374 PubMed40836297

2025

The integrated stress response promotes macrophage inflammation and migration in autoimmune diabetes.

Applications

Unspecified application

Species

Unspecified reactive species

Jiayi E Wang,Charanya Muralidharan,Armando A Puente,Titli Nargis,Jacob R Enriquez,Ryan M Anderson,Raghavendra G Mirmira,Sarah A Tersey

Journal for immunotherapy of cancer 13: PubMed40789740

2025

Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48.

Applications

Unspecified application

Species

Unspecified reactive species

Jiatong Xiao,Jinhui Liu,Chunyu Zhang,Zhi Liu,Zhenyu Nie,Zhenglin Yi,Xin Gao,Haisu Liang,Jinliang Huang,Zhiyong Cai,Luzhe Yan,Bingquan Wu,Zefu Liu,Jinbo Chen,Xiongbing Zu,Jiao Hu

Cancer management and research 17:1503-1512 PubMed40727589

2025

Ginseng-Derived Exosomes Attenuate Immune Evasion in NSCLC via PD-L1 Modulation.

Applications

Unspecified application

Species

Unspecified reactive species

Lin-Jia Zhu,Xiao-Qiang Chen,Qiu-Yan Lin,Jie-Ni Feng,Shao-Fei Yuan

Nature communications 16:4564 PubMed40379682

2025

USP2 inhibition unleashes CD47-restrained phagocytosis and enhances anti-tumor immunity.

Applications

Unspecified application

Species

Unspecified reactive species

Panpan Dai,Yishuang Sun,Zhengrong Huang,Yu-Tong Liu,Minling Gao,Hai-Ming Liu,Jie Shi,Chuan He,Bolin Xiang,Yingmeng Yao,Haisheng Yu,Gaoshan Xu,Lijun Kong,Xiangling Xiao,Xiyong Wang,Xue Zhang,Wenjun Xiong,Jing Hu,Dandan Lin,Bo Zhong,Gang Chen,Yan Gong,Conghua Xie,Jinfang Zhang

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 12:e04860 PubMed40364727

2025

A pH-Sensitive Nanosized Covalent-Organic Polymer for Enhanced Tumor Photodynamic Immunotherapy by Hypoxia Relief and STAT3 Inhibition.

Applications

Unspecified application

Species

Unspecified reactive species

Lei Lei,Wenbin Dai,Jinchao Zhao,Angfeng Jiang,Haisheng Peng,Qiao Jin,Xiaojing Li,Zhe Tang

Nature genetics 57:680-693 PubMed40069506

2025

Alterations in PD-L1 succinylation shape anti-tumor immune responses in melanoma.

Applications

Unspecified application

Species

Unspecified reactive species

Long Liang,Xinwei Kuang,Yi He,Lin Zhu,Poyee Lau,Xin Li,Dingan Luo,Lan Gong,Wenbin Zhou,Fanglin Zhang,Xiaowei Liang,Zhuofeng Li,Bin Hu,Dandan Liu,Tao Ding,Hui Li,Shuang Zhao,Juan Su,Mien-Chie Hung,Jing Liu,Hong Liu,Xiang Chen

Cells 14: PubMed39996786

2025

A Critical Role of Intracellular PD-L1 in Promoting Ovarian Cancer Progression.

Applications

Unspecified application

Species

Unspecified reactive species

Rui Huang,Brad Nakamura,Rosemary Senguttuvan,Yi-Jia Li,Antons Martincuks,Rania Bakkar,Mihae Song,David K Ann,Lorna Rodriguez-Rodriguez,Hua Yu
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com